Literature DB >> 23958466

Levels and actions of progesterone and its metabolites in the nervous system during physiological and pathological conditions.

Roberto Cosimo Melcangi1, Silvia Giatti2, Donato Calabrese2, Marzia Pesaresi3, Gaia Cermenati2, Nico Mitro2, Barbara Viviani2, Luis Miguel Garcia-Segura4, Donatella Caruso2.   

Abstract

Progesterone is synthesized and actively metabolized in the central and peripheral nervous system, into neuroactive steroid metabolites, such as dihydroprogesterone, allopregnanolone and isopregnanolone. Progesterone and/or its metabolites exert a variety of effects acting as physiological regulators of neuronal and glial development and plasticity, controlling reproduction, neuroendocrine events, mood and affection. In addition, these neuroactive steroids maintain neural homeostasis and exert neuroprotective actions. In agreement, metabolic pathways of progesterone are affected by modifications in the level of gonadal hormones and by pathology or injury with a regional specificity and in a sex-dimorphic way. Therefore, observations here summarized may provide a background to design sex-specific therapies based on progesterone metabolites. On this point of view, considering that one of the major limits of a therapy based on neuroactive steroids could be modifications in their plasma levels and their consequent peripheral effects, pharmacological treatments aimed to increase their levels in the nervous system could provide an interesting therapeutic option.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3α,5α-tetrahydroprogesterone; 3α-HSOR; 3α-THP; 3α-hydroxysteroid oxidoreductase; 3β,5α-tetrahydroprogesterone; 3β-HSD; 3β-HSOR; 3β-THP; 3β-hydroxysteroid dehydrogenase; 3β-hydroxysteroid oxidoreductase; 5α-R; 5α-reductase; Allopregnanolone; CNS; DHP; EAE; Gonadectomy; Iba1; LC-MS/MS; LXR; MBP; Metabolism; Neuroactive steroids; Neurodegeneration; Neuroprotection; P0; P450 side-chain cleavage enzyme; P450scc; PMP22; PNS; PR; PREG; PROG; STZ; StAR; TSPO; WT; central nervous system; dihydroprogesterone; experimental autoimmune encephalomyelitis; glycoprotein zero; ionized calcium-binding adapter molecule 1; liquid chromatography tandem mass spectrometry; liver X receptor; myelin basic protein; peripheral myelin protein 22; peripheral nervous system; pregnenolone; progesterone; progesterone receptor; steroidogenic acute regulatory protein; streptozotocin; translocator protein of 18 kDa; wild type

Mesh:

Substances:

Year:  2013        PMID: 23958466     DOI: 10.1016/j.pneurobio.2013.07.006

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  28 in total

Review 1.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 2.  Investigational agents for treatment of traumatic brain injury.

Authors:  Ye Xiong; Yanlu Zhang; Asim Mahmood; Michael Chopp
Journal:  Expert Opin Investig Drugs       Date:  2015-03-01       Impact factor: 6.206

3.  Sex differences in neurosteroid and hormonal responses to metyrapone in posttraumatic stress disorder.

Authors:  Sabra S Inslicht; Anne Richards; Erin Madden; Madhu N Rao; Aoife O'Donovan; Lisa S Talbot; Evelyn Rucker; Thomas J Metzler; Richard L Hauger; Thomas C Neylan
Journal:  Psychopharmacology (Berl)       Date:  2014-06-21       Impact factor: 4.530

Review 4.  Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?

Authors:  Silvia Giatti; Silvia Diviccaro; Giancarlo Panzica; Roberto Cosimo Melcangi
Journal:  Endocrine       Date:  2018-04-19       Impact factor: 3.633

Review 5.  Neurosteroidogenesis Today: Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research.

Authors:  P Porcu; A M Barron; C A Frye; A A Walf; S-Y Yang; X-Y He; A L Morrow; G C Panzica; R C Melcangi
Journal:  J Neuroendocrinol       Date:  2016-02       Impact factor: 3.627

6.  BDNF concentrations and daily fluctuations differ among ADHD children and respond differently to methylphenidate with no relationship with depressive symptomatology.

Authors:  Isabel Cubero-Millán; María-José Ruiz-Ramos; Antonio Molina-Carballo; Sylvia Martínez-Serrano; Luisa Fernández-López; Irene Machado-Casas; Pilar Tortosa-Pinto; Aida Ruiz-López; Juan-de-Dios Luna-Del-Castillo; José Uberos; Antonio Muñoz-Hoyos
Journal:  Psychopharmacology (Berl)       Date:  2016-11-03       Impact factor: 4.530

7.  Distinct cognitive effects of estrogen and progesterone in menopausal women.

Authors:  Alison Berent-Spillson; Emily Briceno; Alana Pinsky; Angela Simmen; Carol C Persad; Jon-Kar Zubieta; Yolanda R Smith
Journal:  Psychoneuroendocrinology       Date:  2015-05-14       Impact factor: 4.905

Review 8.  Allopregnanolone and Progesterone in Experimental Neuropathic Pain: Former and New Insights with a Translational Perspective.

Authors:  Susana Laura González; Laurence Meyer; María Celeste Raggio; Omar Taleb; María Florencia Coronel; Christine Patte-Mensah; Ayikoe Guy Mensah-Nyagan
Journal:  Cell Mol Neurobiol       Date:  2018-09-05       Impact factor: 5.046

Review 9.  Neuroactive Steroids and Sex-Dimorphic Nervous Damage Induced by Diabetes Mellitus.

Authors:  Silvia Giatti; Silvia Diviccaro; Roberto Cosimo Melcangi
Journal:  Cell Mol Neurobiol       Date:  2018-08-14       Impact factor: 5.046

10.  Inhibitory respiratory responses to progesterone and allopregnanolone in newborn rats chronically treated with caffeine.

Authors:  NagaPraveena Uppari; Vincent Joseph; Aida Bairam
Journal:  J Physiol       Date:  2015-12-14       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.